Correction.
An article reporting a congressional hearing on the National Cancer Institute (NCI) (News and Comment, 20 Nov., p. 887) incorrectly states that the institute allowed an unnamed individual to produce a preparation called "Jim's Juice" under what is known as a "compassionate investigational new drug" permit. The NCI, which does not have authority to issue such IND's, was not involved in the matter. The article also refers to an internal memo written by an NCI researcher about the alleged misuse of an experimental drug called Mitoxantrone. The drug in question was one known as M-AMSA, a new agent against acute leukemia.